Back to Search Start Over

Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome

Authors :
Raghuram, Nikhil
Hasegawa, Daisuke
Nakashima, Kentaro
Rahman, Syaza
Antoniou, Evangelia
Skajaa, Torjus
Merli, Pietro
Verma, Anupam
Rabin, Karen R.
Aftandilian, Catherine
Kotecha, Rishi S.
Cheuk, Daniel
Jahnukainen, Kirsi
Kolenova, Alexandra
Balwierz, Walentyna
Norton, Alice
O’Brien, Maureen
Cellot, Sonia
Chopek, Ashley
Arad-Cohen, Nira
Goemans, Bianca
Rojas-Vasquez, Marta
Ariffin, Hany
Bartram, Jack
Kolb, E. Anders
Locatelli, Franco
Klusmann, Jan-Henning
Hasle, Henrik
McGuire, Bryan
Hasnain, Afia
Sung, Lillian
Hitzler, Johann
Source :
Blood Advances; November 2023, Vol. 7 Issue: 21 p6532-6539, 8p
Publication Year :
2023

Abstract

•Treatment outcomes for relapsed or refractory ML-DS remain dismal in a contemporary treatment period (3-year OS 22%).•Patients who had a long duration of first remission, achieved a second remission and underwent HSCT were most likely to survive.

Details

Language :
English
ISSN :
24739529 and 24739537
Volume :
7
Issue :
21
Database :
Supplemental Index
Journal :
Blood Advances
Publication Type :
Periodical
Accession number :
ejs62193201
Full Text :
https://doi.org/10.1182/bloodadvances.2022009381